181 related articles for article (PubMed ID: 37315847)
1. Targeting plasma cells in systemic autoimmune rheumatic diseases - Promises and pitfalls.
Steinmetz TD; Verstappen GM; Suurmond J; Kroese FGM
Immunol Lett; 2023 Aug; 260():44-57. PubMed ID: 37315847
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus.
Szabó K; Papp G; Szántó A; Tarr T; Zeher M
Clin Exp Immunol; 2016 Jan; 183(1):76-89. PubMed ID: 26358223
[TBL] [Abstract][Full Text] [Related]
3. [Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].
Ampélas JF; Wattiaux MJ; Van Amerongen AP
Encephale; 2001; 27(6):588-99. PubMed ID: 11865567
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody repertoire characterization provides insight into the pathogenesis of monogenic and polygenic autoimmune diseases.
Clarke T; Du P; Kumar S; Okitsu SL; Schuette M; An Q; Zhang J; Tzvetkov E; Jensen MA; Niewold TB; Ferre EMN; Nardone J; Lionakis MS; Vlach J; DeMartino J; Bender AT
Front Immunol; 2023; 14():1106537. PubMed ID: 36845162
[TBL] [Abstract][Full Text] [Related]
5. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches.
Merino-Vico A; Frazzei G; van Hamburg JP; Tas SW
Eur J Immunol; 2023 Jan; 53(1):e2149675. PubMed ID: 36314264
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
Rietveld A; van den Hoogen LL; Bizzaro N; Blokland SLM; Dähnrich C; Gottenberg JE; Houen G; Johannsen N; Mandl T; Meyer A; Nielsen CT; Olsson P; van Roon J; Schlumberger W; van Engelen BGM; Saris CGJ; Pruijn GJM
Front Immunol; 2018; 9():1200. PubMed ID: 29922285
[TBL] [Abstract][Full Text] [Related]
7. A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjögren's Syndrome.
Ortíz-Fernández L; Martín J; Alarcón-Riquelme ME
Clin Rev Allergy Immunol; 2023 Jun; 64(3):392-411. PubMed ID: 35749015
[TBL] [Abstract][Full Text] [Related]
8. Ro52/TRIM21 - From host defense to autoimmunity.
Holwek E; Opinc-Rosiak A; Sarnik J; Makowska J
Cell Immunol; 2023; 393-394():104776. PubMed ID: 37857191
[TBL] [Abstract][Full Text] [Related]
9. A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases.
Simon Q; Grasseau A; Boudigou M; Le Pottier L; Bettachioli E; Cornec D; Rouvière B; Jamin C; Le Lann L; ; ; Borghi MO; Aguilar-Quesada R; Renaudineau Y; Alarcón-Riquelme ME; Pers JO; Hillion S
Arthritis Rheumatol; 2021 Aug; 73(8):1550-1561. PubMed ID: 33605069
[TBL] [Abstract][Full Text] [Related]
10. T follicular helper cell subsets: a potential key player in autoimmunity.
Kurata I; Matsumoto I; Sumida T
Immunol Med; 2021 Mar; 44(1):1-9. PubMed ID: 32546108
[TBL] [Abstract][Full Text] [Related]
11. Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis.
Chan EKL
Clin Rev Allergy Immunol; 2022 Oct; 63(2):178-193. PubMed ID: 35040083
[TBL] [Abstract][Full Text] [Related]
12. Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system.
Hysa E; Cutolo CA; Gotelli E; Paolino S; Cimmino MA; Pacini G; Pizzorni C; Sulli A; Smith V; Cutolo M
Autoimmun Rev; 2021 May; 20(5):102796. PubMed ID: 33722750
[TBL] [Abstract][Full Text] [Related]
13. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins.
Scofield RH; Farris AD; Horsfall AC; Harley JB
Arthritis Rheum; 1999 Feb; 42(2):199-209. PubMed ID: 10025913
[TBL] [Abstract][Full Text] [Related]
14. Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine.
Quartuccio L; De Marchi G; Longhino S; Manfrè V; Rizzo MT; Gandolfo S; Tommasini A; De Vita S; Fox R
Front Immunol; 2021; 12():703780. PubMed ID: 34322134
[TBL] [Abstract][Full Text] [Related]
15. The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren's syndrome.
Scuron MD; Fay BL; Connell AJ; Oliver J; Smith PA
Int Immunopharmacol; 2021 Sep; 98():107904. PubMed ID: 34214886
[TBL] [Abstract][Full Text] [Related]
16. IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren's syndrome, and drug-induced autoimmunity.
Rubin RL; Tang FL; Chan EK; Pollard KM; Tsay G; Tan EM
J Immunol; 1986 Oct; 137(8):2528-34. PubMed ID: 3760566
[TBL] [Abstract][Full Text] [Related]
17. Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases.
Murng SHK; Thomas M
J Clin Pathol; 2018 Jan; 71(1):12-19. PubMed ID: 28663326
[TBL] [Abstract][Full Text] [Related]
18. Role of B cells in Sjögren's syndrome--from benign lymphoproliferation to overt malignancy.
Jonsson R; Nginamau E; Szyszko E; Brokstad KA
Front Biosci; 2007 Jan; 12():2159-70. PubMed ID: 17127453
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune thyroid disease in systemic lupus erythematosus and Sjögren's syndrome.
Scofield RH
Clin Exp Rheumatol; 1996; 14(3):321-30. PubMed ID: 8809450
[TBL] [Abstract][Full Text] [Related]
20. Ganglionic Acetylcholine Receptor Antibodies and Autonomic Dysfunction in Autoimmune Rheumatic Diseases.
Imamura M; Mukaino A; Takamatsu K; Tsuboi H; Higuchi O; Nakamura H; Abe S; Ando Y; Matsuo H; Nakamura T; Sumida T; Kawakami A; Nakane S
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
